A patent review of BRD4 inhibitors (2013-2019)

References

• Arrowsmith CH, Bountra C, Fish PV, et al. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov. 2012;11(5):384–400.
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067–1073.
   PubMed Web of Science ®Google Scholar
• Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325(5942):834–840.
   PubMed Web of Science ®Google Scholar
• Zeng L, Zhou MM. Bromodomain: an acetyl-lysine binding domain. FEBS Lett. 2002;513(1):124–128.
   PubMed Web of Science ®Google Scholar
• Coude MM, Braun T, Berrou J, et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget. 2015;6(19):17698–17712.
   PubMedGoogle Scholar
• Alqahtani A, Choucair K, Ashraf M, et al. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA. 2019;5(3):FSO372.
   PubMed Web of Science ®Google Scholar
• Ali I, Choi G, Lee K. BET inhibitors as anticancer agents: a patent review. Recent Pat Anticancer Drug Discov. 2017;12(4):340–364.
   PubMed Web of Science ®Google Scholar
• Bennett RL, Licht JD. Targeting Epigenetics in cancer. Annu Rev Pharmacol Toxicol. 2018;58:187–207.
   PubMed Web of Science ®Google Scholar
• Cochran AG, Conery AR, Sims RJ 3rd. Bromodomains: a new target class for drug development. Nat Rev Drug Discov. 2019;18(8):609–628.
   PubMed Web of Science ®Google Scholar
• Jang MK, Mochizuki K, Zhou M, et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005;19(4):523–534.
   PubMed Web of Science ®Google Scholar
• Vollmuth F, Blankenfeldt W, Geyer M. Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution. J Biol Chem. 2009;284(52):36547–36556.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Li T, Price DH. RNA polymerase II elongation control. Annu Rev Biochem. 2012;81:119–143.
   PubMed Web of Science ®Google Scholar
• Wu SY, Chiang CM. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem. 2007;282(18):13141–13145.
   PubMed Web of Science ®Google Scholar
• Yang Z, Yik JH, Chen R, et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005;19(4):535–545.
   PubMed Web of Science ®Google Scholar
• Li GQ, Guo WZ, Zhang Y, et al. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Oncotarget. 2016;7(3):2462–2474.
   PubMedGoogle Scholar
• Wu X, Liu D, Tao D, et al. BRD4 regulates EZH2 transcription through upregulation of C-MYC and represents a novel therapeutic target in bladder cancer. Mol Cancer Ther. 2016;15(5):1029–1042.
   PubMed Web of Science ®Google Scholar
• Huang B, Yang XD, Zhou MM, et al. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol. 2009;29(5):1375–1387.
   PubMed Web of Science ®Google Scholar
• Crowe BL, Larue RC, Yuan C, et al. Structure of the Brd4 ET domain bound to a C-terminal motif from gamma-retroviral integrases reveals a conserved mechanism of interaction. Proc Natl Acad Sci U S A. 2016;113(8):2086–2091.
   PubMed Web of Science ®Google Scholar
• Perez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications. Epigenetics. 2017;12(5):323–339.
   PubMed Web of Science ®Google Scholar
• Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524–528.
   PubMed Web of Science ®Google Scholar
• Toyoshima M, Howie HL, Imakura M, et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A. 2012;109(24):9545–9550.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478(7370):529–533.
   PubMed Web of Science ®Google Scholar
• Baker EK, Taylor S, Gupte A, et al. BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. Sci Rep. 2015;5:10120.
   PubMed Web of Science ®Google Scholar
• Wu X, Liu D, Gao X, et al. Inhibition of BRD4 suppresses cell proliferation and induces apoptosis in renal cell carcinoma. Cell Physiol Biochem. 2017;41(5):1947–1956.
   PubMedGoogle Scholar
• Latil A, Vidaud D, Valeri A, et al. htert expression correlates with MYC over-expression in human prostate cancer. Int J Cancer. 2000;89(2):172–176.
   PubMed Web of Science ®Google Scholar
• Wang R, Liu W, Helfer CM, et al. Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma. Cancer Res. 2014;74(12):3332–3343.
   PubMed Web of Science ®Google Scholar
• Wang R, Cao XJ, Kulej K, et al. Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma. Proc Natl Acad Sci U S A. 2017;114(27):E5352–E61.
   PubMed Web of Science ®Google Scholar
• Shu S, Lin CY, He HH, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529(7586):413–417.
   PubMed Web of Science ®Google Scholar
• Gao Z, Yuan T, Zhou X, et al. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression. Cancer Biol Ther. 2018;19(5):407–415.
   PubMed Web of Science ®Google Scholar
• Segura MF, Fontanals-Cirera B, Gaziel-Sovran A, et al. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res. 2013;73(20):6264–6276.
   PubMed Web of Science ®Google Scholar
• Tan Y, Wang L, Du Y, et al. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression. Int J Oncol. 2018;53(6):2503–2517.
   PubMed Web of Science ®Google Scholar
• Urano E, Kariya Y, Futahashi Y, et al. Identification of the P-TEFb complex-interacting domain of Brd4 as an inhibitor of HIV-1 replication by functional cDNA library screening in MT-4 cells. FEBS Lett. 2008;582(29):4053–4058.
   PubMed Web of Science ®Google Scholar
• Li Z, Guo J, Wu Y, et al. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res. 2013;41(1):277–287.
   PubMed Web of Science ®Google Scholar
• Hishiki K, Akiyama M, Kanegae Y, et al. NF-kappaB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells. Leuk Res. 2018;74:57–63.
   PubMed Web of Science ®Google Scholar
• Garnier JM, Sharp PP, Burns CJ. BET bromodomain inhibitors: a patent review. Expert Opin Ther Pat. 2014;24(2):185–199.
   PubMed Web of Science ®Google Scholar
• Koblan LW, Buckley DL, Ott CJ, et al. Assessment of Bromodomain Target Engagement by a Series of BI2536 Analogues with Miniaturized BET-BRET. ChemMedChem. 2016;11(23):2575–2581.
   PubMed Web of Science ®Google Scholar
• Long J, Li B, Rodriguez-Blanco J, et al. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers. J Biol Chem. 2014;289(51):35494–35502.
   PubMed Web of Science ®Google Scholar
• Gosmini R, Nguyen VL, Toum J, et al. The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor. J Med Chem. 2014;57(19):8111–8131.
   PubMed Web of Science ®Google Scholar
• McDaniel KF, Wang L, Soltwedel T, et al. Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin −4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a potent and orally available Bromodomain and Extraterminal Domain (BET) family bromodomain inhibitor. J Med Chem. 2017;60(20):8369–8384.
   PubMed Web of Science ®Google Scholar
• Ghoshal A, Yugandhar D, Srivastava AK. BET inhibitors in cancer therapeutics: a patent review. Expert Opin Ther Pat. 2016;26(4):505–522.
   PubMed Web of Science ®Google Scholar
• Mitsubishi Tanabe Pharma Corporation. Antitumor agent. WO 2009084693. 2009
   Google Scholar
• Oncoethix Gmbh. Methods of treating lymphoma using thienotriazolodiazepine compounds. WO2016026912A1. 2016.
   Google Scholar
• Oncoethix Sa. Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds. WO2015078928A1. 2015.
   Google Scholar
• Oncoethix Sa. A Bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma. WO201518520A1. 2015.
   Google Scholar
• Bayer Pharma AG. 6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines. WO2013030150A1. 2013.
   Google Scholar
• Bayer Pharma AG. 4-substituted pyrrolo- and pyrazolo-diazepines. WO2014128111A1. 2014.
   Google Scholar
• Bayer Pharma AG. Bet protein-inhibiting 5-aryl triazole azepines. WO2014048945A1. 2014.
   Google Scholar
• Bayer Pharma AG. 2,3-benzodiazepines. WO 2014026997A1. 2014.
   Google Scholar
• Bayer Pharma AG. Substituted phenyl-2,3-benzodiazepines. WO 2014202578A1. 2014.
   Google Scholar
• Bayer Pharma AG. 6,9-disubstituted 1-phenyl-3H-2,3-benzodiazepines and their use as bromodomain inhibitors. WO 2015121227A1.2015.
   Google Scholar
• Bayer Pharma AG. 6-substituted 2,3-benzodiazepines. WO 2015121226A1. 2014
   Google Scholar
• Bayer Pharma AG. 1-phenyl-3h-2,3-benzodiazepines and their use as bromodomain inhibitors. WO 2015121268A1. 2015.
   Google Scholar
• Bayer Pharma AG. 9-substituted 2,3-benzodiazepines. WO 2015121230A1. 2015.
   Google Scholar
• Bayer Pharma AG.1-phenyl-3H-2,3-benzodiazepines and their useas bromodomain inhibitors. WO 2016062688A1. 2016.
   Google Scholar
• Bayer Pharma AG. N-sulphoximinophenyl-substituted benzodiazepine derivatives as bet protein inhibitors. WO 2017063959A1. 2017.
   Google Scholar
• Bayer Pharma AG. 2-substituted 5-(phenyl)-1,2-dihydro-3h-3-benzazepine-3-carboxamide derivatives as brd4 inhibitors for the treatment of cancer. WO 2017144393A1. 2017.
   Google Scholar
• Kainos Medicine, Inc. Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer. WO2015156601A1. 2015.
   Google Scholar
• Kainos Medicine, Inc. Bromodomain-inhibiting compounds and methods to prevent or treat a cancer. WO2016171470A1. 2016.
   Google Scholar
• Tensha Therapeutics, Inc. Bromodomain inhibitors. WO2016069578A1. 2016.
   Google Scholar
• Shanghai institute of pharmacology. Brd4 inhibitor, preparation and application thereof. WO2018188660A1. 2018.
   Google Scholar
• Hivnova Pharmaceuticals Inc. BRD4 Inhibitor. WO2019052519A1. 2019.
   Google Scholar
• Abbvie Inc. Fused tetracyclic bromodomain inhibitors. WO2014164780A1. 2014.
   Google Scholar
• Abbvie Inc. Tetracyclic bromodomain inhibitors. WO2014139324A1. 2014.
   Google Scholar
• Jubilant Biosys Limited. Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer. WO2016157221A1. 2016.
   Google Scholar
• Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors. WO2013027168A1. 2013.
   Google Scholar
• Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-faMily bromodomain inhibitors. WO20162033351A1. 2016.
   Google Scholar
• GlaxoSmithKline.Inc. 2,3-disubstituted 1-acyl-4-aMino-1,2,3,4-tetrahydroquinoline derivatives and their use as broModoMain inhibitors. WO2014140076A1. 2014.
   Google Scholar
• GlaxoSmithKline.Inc. Tetrahydroquinoline derivatives as bromodomain inhibitors. WO2016038120A1. 2016.
   Google Scholar
• GlaxoSmithKline.Inc. Tetrahydroquinoline coMpositions as bet bromodomain inhibitors. WO201574064A1. 2015.
   Google Scholar
• Bayer PharMa AG. Modified bet-protein-inhibiting dihydroquinoxalinones and dihydropyridopyrazinones. WO2015004075A1. 2015.
   Google Scholar
• Bayer PharMa AG. Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases. WO2015011084A1. 2015.
   Google Scholar
• Bayer PharMa AG. Substituted 3,4-dihydro-pyrido [2,3-b] pyrazin-2 (1H) –one. DE102017005091A1. 2017.
   Google Scholar
• Bayer PharMa AG. Substitulerte 3,4-dihydroquinoxalin-2 (1H) –one. DE102017005089A1. 2017.
   Google Scholar
• Shanghai institute of pharmacology. Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation Method and use thereof. WO2018161876A1. 2018.
   Google Scholar
• Shanghai institute of pharmacology. Inhibitors of bromodomain-containing protein 4 (brd4). WO2018112037A1. 2018.
   Google Scholar
• Boehringer Ingelheim Inc. Dihydroquinazolinone analogues as BRD4 inhibitors. WO2014154762A1. 2014.
   Google Scholar
• China pharmaceutical University. Bromodomain protein divalent inhibitors and preparation method and applications thereof. CN107056771A. 2017.
   Google Scholar
• Nuevolution A/S. Compounds active towards bromodomains. WO2016016316A1. 2016.
   Google Scholar
• Shanghai institute of pharmacology. The application of 8-hydroxyquinoline class drug or its salt in the drug that preparation is used to treat disease relevant to BRD4. CN109106715A. 2018.RVX Therapeutics Inc. Cyclic amines as bromodomain inhibitors. US20140142102A1.2 014.
   Google Scholar
• China pharmaceutical university. Preparation method and application of pyrrole [4,3,2-de] quinoline-2-(1H)-ketone BRD4 protein inhibitor. CN105732624A. 2016
   Google Scholar
• Abbvie Inc. Bromodomain inhibitors. WO2013097601A1. 2013
   Google Scholar
• Abbvie Inc. Bromodomain inhibitors. WO2014206150A1. 2014
   Google Scholar
• Abbvie Inc. Bromodomain inhibitors. WO2015085925A1. 2015
   Google Scholar
• Abbvie Inc. Bromodomain inhibitors. WO2015089075A1. 2015
   Google Scholar
• Abbvie Inc. Bromodomain inhibitors. WO2018068282A1. 2018
   Google Scholar
• Abbvie Inc. Bromodomain inhibitors. WO2018068283A1. 2018
   Google Scholar
• Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors. WO2015058160A1. 2015
   Google Scholar
• Celgene Quanticel Research, Inc. Bromodomain inhibitors. WO2016168682A1. 2016
   Google Scholar
• Celgene Quanticel Research, Inc. Therapeutic compounds. US20170298040A1. 2017
   Google Scholar
• Boehringer Ingelheim International Gmbh. Triazolopyrazine. WO2014076237A1. 2014
   Google Scholar
• Boehringer Ingelheim International Gmbh. Triazolopyrazine derivatives as brd4 inhibitors. WO2015067770A1. 2015
   Google Scholar
• Korea institute of chemistry. Novel [1,2,4]triazolo[4, 3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating bet protein-related diseases, containing same as active ingredient. WO2018139876A1. 2018.
   Google Scholar
• Korea institute of chemistry. Phenylamino-[1,2,4]triazolo[4,3-a]quinoxaline derivative for treating BET protein-related disease, and method for the preparation thereof. KR2018106597A1. 2018.
   Google Scholar
• Novartis AG Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease. US2014034990A1. 2014.
   Google Scholar
• Neomed Institute. Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals. WO2017127930A1. 2017.
   Google Scholar
• Shandong Luoxin pharmaceutical, LTD. Nitrogen-containing heterocyclic compounds, preparation method therefor, pharmaceutical composition thereof, and applications thereof. WO2018086585A1.2018.
   Google Scholar
• Abbvie Inc. Isoindolone derivatives. WO2013158952A1. 2013.
   Google Scholar
• Abbvie Inc. Pyrrole amide inhibitors. WO2014165127A1. 2014.
   Google Scholar
• China Pharmaceutical University. Preparation method and purpose of pyrrolone BRD4 protein inhibitor. CN107739370A. 2017.
   Google Scholar
• Novartis AG Pyrrolopyrrolone derivatives and their use as BET inhibitors. WO2015075665A1. 2015.
   Google Scholar
• Gilead Sciences Inc. Synthesis of a compound that modulates the activity of bromodomain-containing proteins. US2018017991A1. 2017.
   Google Scholar
• Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors. WO2015002754A2. 2015.
   Google Scholar
• Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors. WO2015004533A2. 2015.
   Google Scholar
• Zenith Epigenetics Corp. Substituted pyridines as bromodomain inhibitors. WO2015004534A2. 2015.
   Google Scholar
• Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors. WO2016087936A1. 2016.
   Google Scholar
• Zenith Epigenetics Corp. Substituted pyridines as bromodomain inhibitors. WO2016087942A1. 2016
   Google Scholar
• Zenith Epigenetics Corp. Substituted bicyclic compounds as bromodomain inhibitors. WO2016097870A1. 2016.
   Google Scholar
• Zenith Epigenetics Corp. Inhibitors of bromodomains. WO2016097863A1. 2016.
   Google Scholar
• Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors. WO2016092375A1. 2016.
   Google Scholar
• Liu Z, Wang P, Chen H, et al. Drug discovery targeting bromodomain-containing protein 4. J Med Chem. 2017;60(11):4533–4558.
   PubMed Web of Science ®Google Scholar
• Winter GE, Buckley DL, Paulk J, et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348(6241):1376–1381.
   PubMed Web of Science ®Google Scholar
• Gadd MS, Testa A, Lucas X, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017 May;13(5):514–521.
   PubMed Web of Science ®Google Scholar
• Lu J, Qian Y, Altieri M, et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol. 2015;22(6):755–763.
   PubMedGoogle Scholar
• Hines J, Lartigue S, Dong H, et al. MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53. Cancer Res. 2019 Jan 1;79(1):251–262.
   PubMed Web of Science ®Google Scholar
• Zhou B, Hu J, Xu F, et al. Discovery of a small-molecule degrader of Bromodomain and Extra-Terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J Med Chem. 2018 Jan 25;61(2):462–481.
   PubMed Web of Science ®Google Scholar
• Heerboth S, Lapinska K, Snyder N, et al. Use of epigenetic drugs in disease: an overview. Genet Epigenet. 2014;6:9–19.
   PubMedGoogle Scholar
• Devaiah BN, Case-Borden C, Gegonne A, et al. BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin. Nat Struct Mol Biol. 2016;23(6):540–548.
   PubMed Web of Science ®Google Scholar
• Devaiah BN, Lewis BA, Cherman N, et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A. 2012;109(18):6927–6932.
   PubMed Web of Science ®Google Scholar
• Lu T, Hu JC, Lu WC, et al. Identification of small molecule inhibitors targeting the SMARCA2 bromodomain from a high-throughput screening assay. Acta Pharmacol Sin. 2018;39(9):1544–1552.
   PubMed Web of Science ®Google Scholar
• Lu W, Zhang R, Jiang H, et al. Computer-aided drug design in epigenetics. Front Chem. 2018;6:57.
   PubMed Web of Science ®Google Scholar
• Zhang D, Han J, Lu W, et al. Discovery of alkoxy benzamide derivatives as novel BPTF bromodomain inhibitors via structure-based virtual screening. Bioorg Chem. 2019;86:494–500.
   PubMed Web of Science ®Google Scholar
• Baud MGJ, Lin-Shiao E, Cardote T, et al. Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. Science. 2014;346(6209):638–641.
   PubMed Web of Science ®Google Scholar
• Abbvie Inc. Bromodomain inhibitors. WO 2017177955 A1.
   Google Scholar
• Law RP, Atkinson SJ, Bamborough P, et al. Discovery of tetrahydroquinoxalines as bromodomain and Extra-Terminal Domain (BET) inhibitors with selectivity for the second bromodomain. J Med Chem. 2018;61(10):4317–4334.
   PubMed Web of Science ®Google Scholar
• Albrecht BK, Gehling VS, Hewitt MC, et al. Identification of a benzoisoxazoloazepine inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) family as a candidate for human clinical trials. J Med Chem. 2016;59(4):1330–1339.
   PubMed Web of Science ®Google Scholar
• Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976–990.
   PubMed Web of Science ®Google Scholar
• Jin X, Yan Y, Wang D, et al. DUB3 promotes BET inhibitor resistance and cancer progression by deubiquitinating BRD4. Mol Cell. 2018;71(4):592–605 e4.
   PubMed Web of Science ®Google Scholar
• Rathert P, Roth M, Neumann T, et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 2015;525(7570):543–547.
   PubMed Web of Science ®Google Scholar
• Fong CY, Gilan O, Lam EY, et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015;525(7570):538–542.
   PubMed Web of Science ®Google Scholar
• Qin AC, Li Y, Zhou LN, et al. Dual PI3K-BRD4 inhibitor SF1126 inhibits colorectal cancer cell growth in vitro and in vivo. Cell Physiol Biochem. 2019;52(4):758–768.
   PubMedGoogle Scholar
• Deng M, Wang J, Chen Y, et al. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway. Anticancer Drugs. 2015;26(4):422–427.
   PubMed Web of Science ®Google Scholar
• Chen H, Zhou X, Wang A, et al. Evolutions in fragment-based drug design: the deconstruction-reconstruction approach. Drug Discov Today. 2015;20(1):105–113.
   PubMed Web of Science ®Google Scholar